NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage<
02 Oct 2025

AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage

Top line data are expected in early 2026, and the full dataset will be presented thereafter at a scientific conference.
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia<
30 Sep 2025

Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia

Phase 2 trial seeks to establish proof-of-concept of KYN-5356; topline results are expected by Q4 2026
ReproNovo announces clinical trial approval notice for RPN-001 in China<
30 Sep 2025

ReproNovo announces clinical trial approval notice for RPN-001 in China

Key regulatory milestone in the global development of RPN‑001
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001<
25 Sep 2025

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

Reduces cost and de-risks development of VMX-C001 in Japan
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health<
24 Sep 2025

Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health

The studies established the lead asset SYT-510 to be well tolerated in healthy volunteers at all doses with a good safety profile
Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial<
24 Sep 2025

Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial

Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment

Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapy for early-stage breast cancer<
18 Sep 2025

Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapy for early-stage breast cancer

Key findings include an estimated €105 million in savings over 10 years.
VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment<
16 Sep 2025

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

VarmX shareholders to receive initial $117m upfront and further potential milestone payments up to $2.1bn.
Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors<
09 Sep 2025

Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

Expect to share preliminary data from the trial by early to mid-2026
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need<
05 Sep 2025

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Lorundrostat demonstrated significant and clinically meaningful blood pressure reductions across all participant subgroups, with a favorable safety and tolerability profile

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.